The nexus of intellectual property and climate change technologies embodies a dynamic fusion of innovation, environmental stewardship, and legal frameworks. Green patents shine as catalysts for a cleaner future, urging inventors worldwide to devise solutions to climate change. However, challenges, particularly concerning carbon capture and storage, loom large.
Category: Blog
Embracing Traditional Knowledge: A Path to Sustainable Living
Traditional knowledge is deeply rooted in holistic perspectives that acknowledge the interconnectedness of all living beings and ecosystems. Unlike the often compartmentalised approach of modern science, traditional wisdom views nature as a dynamic and interdependent web of relationships.
The Balancing Act: AI and the Challenges of Patent Law in the Age of Innovation
Artificial intelligence (AI) is a cornerstone of innovation in today’s rapidly evolving technological landscape. AI has permeated every sector, promising efficiency, accuracy, and unparalleled advancements from healthcare to finance and transportation education. However, as AI continues to push the boundaries of what is possible, it also presents unique challenges to patent law in the age of AI.
US Patent Office: AI is Not Eligible for Patent Protections
The eligibility for copyright protection to AI-generated content is also a contention. According to established copyright law principles, the original creator of a work is recognised as the rightful copyright holder. Regrettably, the existing Copyright Act of 1957 in India does not explicitly address AI-generated works nor acknowledges artificial intelligence as an author, further contributing to the complexities surrounding copyright eligibility in AI-generated content.
How AI is Revolutionizing the Music Industry’s Approach to Copyright Law
The eligibility for copyright protection to AI-generated content is also a contention. According to established copyright law principles, the original creator of a work is recognised as the rightful copyright holder. Regrettably, the existing Copyright Act of 1957 in India does not explicitly address AI-generated works nor acknowledges artificial intelligence as an author, further contributing to the complexities surrounding copyright eligibility in AI-generated content.
Biosimilars And Patent Challenges in India
India boasts a flourishing biosimilar landscape, with over 100 biopharmaceutical businesses manufacturing and marketing these products. Regulatory authorities in India refer to biosimilars as “similar biologics.” Despite India being an early adopter of the concept, there initially existed no clearly defined guidelines for “similar biologics.”
The Ethics of AI and Intellectual Property: A Discussion on Fair Use and Innovation
The outcomes generated by artificial intelligence (AI) systems may or may not transgress intellectual property laws, with the abovementioned methodologies not imposing any inherent obligation. Assuming the absence of a copyright breach during the input phase, such systems can engender entirely novel works of art devoid of preexistence and, therefore, do not contravene copyright statutes.
India Rejected The Evergreening Patent Application To Increase Access to TB Treatments
India, a proactive player in this high-stakes narrative, has rejected this application, employing a robust set of domestic intellectual property laws. Section 3D of the Indian Patent Act is a crucial weapon in the country’s arsenal, designed to thwart pharmaceutical giants’ “evergreening” tactics.
From Blockchain to Biotech: Indian IP Trends to Watch in 2023
One of the primary reasons behind patent backlogs in India is the surge in patent applications, a testament to the growing significance of the pharmaceutical industry in the country. The sheer volume of applications has strained the capacity of the patent office, leading to delays in the examination and approval process. To cope with this, there is an urgent need for increased staffing, modernised infrastructure, and streamlined processes within the patent office.
Big Pharma Benefits Indian Drug Manufacturer: A New Challenge Before Pharmaceutical Patent
One of the primary reasons behind patent backlogs in India is the surge in patent applications, a testament to the growing significance of the pharmaceutical industry in the country. The sheer volume of applications has strained the capacity of the patent office, leading to delays in the examination and approval process. To cope with this, there is an urgent need for increased staffing, modernised infrastructure, and streamlined processes within the patent office.
Copyright Reserved @2023 United & United Powered by Evirtual Team